NASDAQ:FTXH First Trust Nasdaq Pharmaceuticals ETF (FTXH) Price, Holdings, & News $24.92 -0.47 (-1.85%) As of 12:18 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FTXH alerts:Sign Up Key Stats Today's Range$24.84▼$25.2150-Day Range$23.57▼$28.7252-Week Range$23.28▼$29.72Volume1,710 shsAverage Volume8,831 shsMarket Capitalization$13.71 millionAssets Under Management$20.34 millionDividend Yield1.93%Net Expense Ratio0.60%Aggregate RatingModerate Buy ETF OverviewThe First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.Read More… First Trust Nasdaq Pharmaceuticals ETF ExpensesTypeFTXHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.60%0.57%0.57%0.53%0.53%Other Expenses0.00%0.30%0.48%0.43%0.52%Total Expense0.60%0.70%0.72%0.68%0.71%Fee Waiver0.00%-0.45%-0.49%-0.29%-0.54%Net Expense0.60%0.61%0.63%0.62%0.60% Receive FTXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Trust Nasdaq Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address FTXH ETF News HeadlinesFirst Trust Nasdaq BuyWrite Income ETF declares $0.207 dividendJanuary 22, 2025 | msn.com3 Health Care ETFs You'll Want to Own When the Market RecoversAugust 3, 2022 | stocknews.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.May 13, 2025 | Brownstone Research (Ad)Surprising Analyst 12-Month Target For FTXHMay 25, 2022 | nasdaq.comFirst Trust Nasdaq Pharmaceuticals ETF declares quarterly distribution of $0.0488March 25, 2022 | seekingalpha.comSolid Q4 Earnings Fail to Impress Pharma ETFsFebruary 22, 2022 | nasdaq.comSee More Headlines FTXH ETF - Frequently Asked Questions How have FTXH shares performed this year? First Trust Nasdaq Pharmaceuticals ETF's stock was trading at $26.97 at the start of the year. Since then, FTXH stock has decreased by 7.9% and is now trading at $24.84. View the best growth stocks for 2025 here. Who are First Trust Nasdaq Pharmaceuticals ETF's major shareholders? First Trust Nasdaq Pharmaceuticals ETF's top institutional shareholders include LPL Financial LLC (19.07%), Envestnet Asset Management Inc. (3.42%), Cambridge Investment Research Advisors Inc. (3.01%) and WMG Financial Advisors LLC (2.34%). How do I buy shares of First Trust Nasdaq Pharmaceuticals ETF? Shares of FTXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of First Trust Nasdaq Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that First Trust Nasdaq Pharmaceuticals ETF investors own include Digirad (DRAD), RAIT Financial Trust (RAS), Cummins (CMI), Auxly Cannabis Group (CBWTF), Blueknight Energy Partners (BKEP), Biocept (BIOC) and BioCorRx (BICX). Fund Details IssuerFirst Trust Fund NameFirst Trust Nasdaq Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:FTXH Inception Date9/20/2016 Fund ManagerDaniel Lindquist, Jon Erickson, David McGarel, Roger Testin, Stan Ueland, Chris Peterson, Erik Russo WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkNasdaq US Smart Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings51 Fund Statistics Assets Under Management$20.34 million Average Daily Volume$29,494.00 Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorFirst Trust Advisors L.P. CustodianThe Bank of New York Mellon Corporation DistributorFirst Trust Portfolios L.P. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerOld Mission Options OptionableN/A Short Interest4,500 shs Miscellaneous Outstanding Shares550,000Beta0.70 Creation Unit50,000 Creation Fee$500.00 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report Top 10 FTXH HoldingsJohnson & Johnson (NYSE:JNJ)Holding Weight: 7.72%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 7.11%AbbVie (NYSE:ABBV)Holding Weight: 7.09%Pfizer (NYSE:PFE)Holding Weight: 7.08%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 6.71%Eli Lilly and Company (NYSE:LLY)Holding Weight: 3.84%Gilead Sciences (NASDAQ:GILD)Holding Weight: 3.82%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.81%Zoetis (NYSE:ZTS)Holding Weight: 3.74%Amgen (NASDAQ:AMGN)Holding Weight: 3.73%Full Holdings DetailsFTXH Sector ExposureFTXH Industry Exposure This page (NASDAQ:FTXH) was last updated on 5/13/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.